Announcements Trials
Browse Landscape

Phase

Phase 1 18Phase 2 7Phase 1/2 7Phase EARLY_PHASE1 2Phase NA 1Phase 4 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 146Breast Neoplasms 112Prostatic Neoplasms 59Multiple Myeloma 55Neoplasms 54Lung Neoplasms 49Neoplasm Metastasis 42Colorectal Neoplasms 34Ovarian Neoplasms 33Parkinson Disease 4, Autosomal Dominant Lewy Body 31Leukemia, Lymphocytic, Chronic, B-Cell 31Recurrence 26Leukemia, Myeloid, Acute 26Carcinoma, Renal Cell 25Urinary Bladder Neoplasms 24Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 21Myasthenia Gravis 21Endometrial Neoplasms 21Carcinoma, Hepatocellular 21Squamous Cell Carcinoma of Head and Neck 20Lymphoma, Large B-Cell, Diffuse 20Melanoma 18Lymphoma, Follicular 18Nasopharyngeal Carcinoma 17Fallopian Tube Neoplasms 16Pancreatic Neoplasms 15Non-Muscle Invasive Bladder Neoplasms 15Brain Neoplasms 15Stomach Neoplasms 14

Interventions

pertuzumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Solid Tumors × 90 days × Clear all
NCT02320435 2026-05-12

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Hoffmann-La Roche

Phase 3 Active not recruiting
154 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡